
- /
- Supported exchanges
- / US
- / GHRS.NASDAQ
GH Research PLC (GHRS NASDAQ) stock market data APIs
GH Research PLC Financial Data Overview
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get GH Research PLC data using free add-ons & libraries
Get GH Research PLC Fundamental Data
GH Research PLC Fundamental data includes:
- Net Revenue:
- EBITDA: -51 455 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: -0.35
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GH Research PLC News

JMP reiterates GH Research stock rating on competitor's positive results
Investing.com - JMP Securities maintained its Market Outperform rating and $39.00 price target on GH Research PLC (NASDAQ:GHRS) Tuesday, following positive Phase 3 results from a competitor in the p...


Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial
(Bloomberg) -- Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. Most Read from Bloomberg Bezos Wedding...

GH Research submits response to FDA clinical hold for depression drug
DUBLIN - GH Research PLC (NASDAQ:GHRS), a $752 million market cap biotech company whose shares have surged 73% over the past six months, announced Friday it has submitted its complete response to the ...

GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule
DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.